TerminatedPhase 2

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Stopped: Study on clinical hold by FDA

United States38 participantsStarted 2023-07-05

Plain-language summary

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Physician diagnosis of asthma for ≥6 months * Pre-bronchodilator FEV1 of \>40% and \<80% * History of treatment with corticosteroid or hospitalization for worsening asthma * Medium- or high-dose inhaled corticosteroid use Exclusion Criteria: * History of smoking/vaping * History of severe COVID * Serious and/or uncontrolled pulmonary, cardiac, immune system conditions * Requires systemic oral or IV corticosteroids in the month prior to screening

What they're measuring

Proportion of Participants With a Loss of Asthma Control Event as Defined by Criteria Listed

Timeframe: 14 weeks

Trial details

NCT IDNCT05935332

SponsorRAPT Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-06-21

Results submitted2025-05-28

View on ClinicalTrials.gov More Asthma trials